Le Lézard
Classified in: Health
Subjects: LGB, AVO, DEI

Medical associations across the country oppose government efforts to restrict access to care


OTTAWA, ON, March 13, 2024 /CNW/ - Medical associations from coast to coast are deeply concerned about any government proposal that would restrict access to evidence-based medical care for patients, including for the transgender population.

Canadians have the right to make personal choices about their health with the support of their families, the guidance of physicians working with other regulated health professionals and free from ideological intrusion.

There is no one-size-fits-all approach for patients experiencing gender dysphoria. Restricting choices and appropriate care for patients can lead to permanent harm.

We urge all levels of government to consult with physician experts in their field when considering any major changes in policy related to health care impacting the 2SLGTBQ+ community.

SOURCE Canadian Medical Association (CMA)


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: